Preferred Label : dalbavancin;
MeSH note : derivative of A-40926; interferes with peptidoglycan synthesis;
CISMeF synonym : Dalvance;
MeSH hyponym : BI397; BI 397; MDL 64,397; MDL-64397; VER001;
Is substance : O;
UNII : 808UI9MS5K;
Origin ID : C469289;
UMLS CUI : C1172636;
ATC code(s)
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3534482/fr/xydalba-dalbavancine-antibiotique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Dalbavancin hydrochloride (substance)
dalbavancin
infusions, intravenous
infant
child
adolescent
acute disease
skin diseases, bacterial
soft tissue infections
evaluation of the transparency committee
dalbavancin
anti-bacterial agents
---
https://www.has-sante.fr/jcms/p_3481907/fr/xydalba-dalbavancine-infections-bacteriennes-aigues-de-la-peau-et-des-tissus-mous-ibaptm
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
skin diseases, bacterial
acute disease
soft tissue infections
adult
dalbavancin
staphylococcal skin infections
anti-bacterial agents
infusions, intravenous
evaluation of the transparency committee
dalbavancin
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/default-d6182e9e12-10.html
2022
false
false
false
Canada
French
insurance, health, reimbursement
Xydalba
dalbavancin
drug evaluation
canada
skin diseases, bacterial
acute disease
soft tissue infections
anti-bacterial agents
infusions, intravenous
dalbavancin
treatment outcome
---
http://www.has-sante.fr/portail/jcms/c_2735208/fr/xydalba
http://www.has-sante.fr/portail/jcms/c_2735208/fr/xydalba-dalbavancine-antibiotique-de-la-classe-des-glycopeptides
2016
false
false
false
France
French
evaluation of the transparency committee
adult
acute disease
skin diseases, bacterial
soft tissue infections
staphylococcal skin infections
methicillin resistance
Methicillin-Resistant staphylococcus aureus
infusions, intravenous
dalbavancin
dalbavancin
treatment outcome
dalbavancin
continuity of patient care
risk management
drug monitoring
anti-bacterial agents
anti-bacterial agents
guidelines for drug use
teicoplanin
teicoplanin
teicoplanin
---
https://www.ema.europa.eu/medicines/human/EPAR/Xydalba
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
dalbavancin
dalbavancin
dalbavancin
drug approval
europe
anti-bacterial agents
anti-bacterial agents
adult
soft tissue infections
skin diseases, bacterial
acute disease
cellulitis
abscess
wound infection
infusions, intravenous
Methicillin resistant Staphylococcus aureus infection (disorder)
Methicillin-Resistant staphylococcus aureus
staphylococcal skin infections
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antibiotic therapy
teicoplanin
teicoplanin
teicoplanin
---